Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Although in vitro observations suggest that cross-presentation of antigens is mediated primarily by CD8alpha+ dendritic cells, in vivo analysis has been hampered by the lack of systems that selectively eliminate this cell lineage. We show that deletion of the transcription factor Batf3 ablated development of CD8alpha+ dendritic cells, allowing us to examine their role in immunity in vivo. Dendritic cells from Batf3-/- mice were defective in cross-presentation, and Batf3-/- mice lacked virus-specific CD8+ T cell responses to West Nile virus. Importantly, rejection of highly immunogenic syngeneic tumors was impaired in Batf3-/- mice. These results suggest an important role for CD8alpha+ dendritic cells and cross-presentation in responses to viruses and in tumor rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“appears essential for T cell-driven antitumor immunity (Hildner et al., 2008)”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
In the citing paper
“Both DC1s and DC2s expressed the DC markers Batf3, Flt3, H2-Dmb2 and Zbtb46 (Meredith et al., 2012; Hildner et al., 2008;); DC1 expressed Fscn1 and Ly 75 (DEC-205) whereas DC2s expressed CD209a (DC- SIGN), Mgl2 (CD301b) and Cd24a (Figure 2B and Figure S2B).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citationJung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Barnden, M. J., Allison, J., Heath, W. R., & Carbone, F. R. (1998) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1998.00709.x · Cited by 1,489
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,328
Steady-state and inflammatory dendritic-cell development
Shortman, K., & Naik, S. H. (2007) · Nature Reviews Immunology · doi:10.1038/nri1996 · Cited by 1,190
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Bevan, M. J. (1976) · The Journal of experimental medicine · doi:10.1084/jem.143.5.1283 · Cited by 956
Toll-like receptor 3 promotes cross-priming to virus-infected cells
Schulz, O., Diebold, S. S., Chen, M., Näslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y.-T., Flavell, R. A., Liljeström, P., & Reis e Sousa, C. (2005) · Nature · doi:10.1038/nature03326 · Cited by 921
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Cited by
Items 701–800 of 1,008
Hatscher, L., Lehmann, C. H. K., Purbojo, A., Onderka, C., Liang, C., Hartmann, A., Cesnjevar, R. A., Bruns, H., Groß, O., Nimmerjahn, F., et al. (2021) · Science Signaling · doi:10.1126/scisignal.abe1757 · Cited by 63
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56
Srirat, T., Hayakawa, T., Mise-Omata, S., Nakagawara, K., Ando, M., Shichino, S., Ito, M., & Yoshimura, A. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113898 · Cited by 56
Lucas, E. D., Schafer, J. B., Matsuda, J. L., Kraus, M., Burchill, M. A., & Tamburini, B. A. J. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108258 · Cited by 60
“…factors, such as basic leucine zipper transcription factor (Batf3) and interferon regulatory factor (IRF) 8 for cDC1s (Aliberti et al., 2003; Hildner et al., 2008) or IRF4 and Notch for cDC2s (Lewis et al., 2011; Schlitzer et al., 2013); express zbtb46; and can be distinguished as either…”
Single-cell analyses reveal early thymic progenitors and pre-B cells in zebrafish
Rubin, S. A., Baron, C. S., Pessoa Rodrigues, C., Duran, M., Corbin, A. F., Yang, S. P., Trapnell, C., & Zon, L. I. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20220038 · Cited by 56
“…et al., 2013; Hason et al., 2022; Haunerdinger et al., 2021; He et al., 2014; Hernandez et al., 2018; Hess and Boehm, 2012; Hey and O ’ Neill, 2016; Hildner et al., 2008; Hinton et al., 2004; Ho et al., 2009; Huang et al., 2020; Ikeda et al., 2017; Iwanami et al., 2011; Jeffrey et al., 2006;…”
Mannosylated STING Agonist Drugamers for Dendritic Cell-Mediated Cancer Immunotherapy
Nguyen, D. C., Song, K., Jokonya, S., Yazdani, O., Sellers, D. L., Wang, Y., Zakaria, A., Pun, S. H., & Stayton, P. S. (2024) · ACS Central Science · doi:10.1021/acscentsci.3c01310 · Cited by 57
Antigen presentation for central tolerance induction
Klein, L., & Petrozziello, E. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01076-8 · Cited by 66
Orlen, M., Vostrejs, W. P., Sor, R., McDevitt, J. C., Kemp, S. B., Kim, I., Kramer, A. B., Shifrin, N. T., Markosyan, N., Clendenin, C., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1475 · Cited by 70
“To determine whether the T-cell effects depend on priming by DCs, we assessed the activity of RMC-7977 in Batf3 −/− mice lacking conventional DCs necessary for antigen cross-presentation to CD8 + T cells (42).”
Dendritic Cell-Based Vaccination in Cancer: Therapeutic Implications Emerging from Murine Models
Keon, S. M., Ruiz, M. S., Gazzaniga, S., & Wainstok, R. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00243 · Cited by 62
“Unlike their wild-type controls, Batf3−/− mice failed to reject syngeneic fibrosarcomas, did not develop tumor-specific CTLs, and showed reduced numbers of tumor-infiltrating CD8 Tcells (104).”
BackgroundSelf-Antigen Presentation by Dendritic Cells in Autoimmunity
Hopp, A.-K., Rupp, A., & Kornek, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00055 · Cited by 67
“Batf3 deficient mice lack CD8 DCs in SLOs and CD103 DCs at the periphery (123).”
BackgroundMayer, C. T., Berod, L., & Sparwasser, T. D. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00183 · Cited by 70
“However, if certain DC subsets are specialized at inducing tolerance in the steady state, it is still not clear why the in vivo elimination of these DC subsets so far failed to elicit autoimmunity (Kaplan et al., 2005; Hildner et al., 2008; Swiecki et al., 2010; Takagi et al., 2011).”
Robertson, S. J., Lubick, K. J., Freedman, B. A., Carmody, A., & Best, S. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302110 · Cited by 60
“DCs are critical for adaptive immunity against flavivirus infections, particularly for generation of CTL responses (42).”
BackgroundWu, T., Wu, X., Wang, H., & Chen, L. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0365-9 · Cited by 67
The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells
Yousif, A. S., Ronsard, L., Shah, P., Omatsu, T., Sangesland, M., Moreno, T. B., Lam, E. C., Vrbanac, V. D., Balazs, A. B., Reinecker, H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.12.001 · Cited by 57
“We also examined Batf3 / mice, which are depleted for cDC1 (Hildner et al., 2008; Figure S3B).”
Patel, R. S., Tomlinson, J. E., Divers, T. J., de Walle, G. R. V., & Rosenberg, B. R. (2021) · BMC Biology · doi:10.1186/s12915-020-00947-5 · Cited by 63
“Cluster 24 also exhibited high expression of BATF3, another characteristic transcription factor of cDC1 [32].”
BackgroundVerheye, E., Melgar, J. B., Deschoemaeker, S., Raes, G., Maes, A., Bruyne, E. D., Menu, E., Vanderkerken, K., Laoui, D., & Veirman, K. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020904 · Cited by 60
“By contrast, Seillet et al. found that these four transcription factors (ID2, IRF8, BATF3, and NFIL3) are necessary for CD103+ cDC1 development, while only IRF8 seems to be important for CD8α+ cDC1s development [63].”
BackgroundSaeki, K., Pan, R., Lee, E., Kurotaki, D., & Ozato, K. (2024) · Nature Immunology · doi:10.1038/s41590-024-01962-2 · Cited by 55
“BATF3, a basic leucine zipper motif family of a TF, is known to be critical for generating a dendritic cell subset 31 .”
Cell-intrinsic innate immune control of West Nile virus infection
Diamond, M., & Gale, M. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.05.008 · Cited by 61
“One recent report showed that selective genetic deletion of CD8α+ mDC resulted in defective cross-presentation and virus-specific CD8+ T cell responses to WNV [24].”
BackgroundWalsh, M. P., Duncan, B. B., Larabee, S. M., Krauss, A. C., Davis, J. P. E., Cui, Y., Kim, S. Y., Guimond, M., Bachovchin, W. W., & Fry, T. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058860 · Cited by 56
“subset being a dendritic cell (DC) [11,12,13].”
Becker, M., Güttler, S., Bachem, A., Hartung, E., Mora, A., Jaekel, A., Hutloff, A., Henn, V., Mages, H. W., Gurka, S., et al. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00326 · Cited by 70
“These studies revealed that CD8α+ DC in the spleen and CD103+ CD11b- DC in the intestine and other organs were specifically absent in animals deficient for the TF Batf3 (Hildner et al., 2008; Edelson et al., 2010).”
BackgroundThe role of the vascular dendritic cell network in atherosclerosis
Alberts‐Grill, N., Denning, T. L., Rezvan, A., & Jo, H. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00017.2013 · Cited by 58
Dendritic Cells in Sepsis: Pathological Alterations and Therapeutic Implications
Wu, D., Li, T., & Ji, X. (2017) · Journal of Immunology Research · doi:10.1155/2017/3591248 · Cited by 65
Critical role of plasmacytoid dendritic cells in induction of oral tolerance
Uto, T., Takagi, H., Fukaya, T., Nasu, J., Fukui, T., Miyanaga, N., Arimura, K., Nakamura, T., Choijookhuu, N., Hishikawa, Y., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.048 · Cited by 63
Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling
Nguyen, K. B., & Spranger, S. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201908224 · Cited by 59
“These cross-presenting DC are critical in priming the antitumor T cell response as they harbor the ability to engulf tumorderived peptides and via cross-presentation present peptide to naive CD8+ T cells (Hildner et al., 2008; Fuertes et al., 2011).”
BackgroundHeger, L., Hatscher, L., Liang, C., Lehmann, C. H. K., Amon, L., Lühr, J. J., Kaszubowski, T., Nzirorera, R., Schaft, N., Dörrie, J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300343120 · Cited by 54
Small Molecule Enhancers of Endosome-to-Cytosol Import Augment Anti-tumor Immunity
Kozik, P., Gros, M., Itzhak, D. N., Joannas, L. D., Heurtebise-Chrétien, S., Krawczyk, P. A., Rodríguez-Silvestre, P., Alloatti, A., Magalhaes, J. G., Nery, E. D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107905 · Cited by 58
“cDC1s appear to bemost efficient cross-presenters in vivo and Batf3 / mice that lack cDC1s, do not mount efficient T cell responses (Hildner et al., 2008).”
BackgroundAging and Options to Halt Declining Immunity to Virus Infections
Palacios-Pedrero, M. Á., Osterhaus, A. D. M. E., Becker, T., Elbahesh, H., Rimmelzwaan, G. F., & Saletti, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681449 · Cited by 61
Mujal, A. M., Combes, A. J., Rao, A. A., Binnewies, M., Samad, B., Tsui, J., Boissonnas, A., Pollack, J. L., Argüello, R. J., Meng, M. V., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0588 · Cited by 60
Strategies to overcome DC dysregulation in the tumor microenvironment
Mestrallet, G., Sone, K., & Bhardwaj, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980709 · Cited by 57
“It has been shown that basic leucine zipper transcription factor ATF-like 3 (BATF3) positive cDC1s are key factors for tumor rejection (10, 13).”
BackgroundBasic and translational applications of engineered MHC class I proteins
Hansen, T. H., Connolly, J. M., Gould, K. G., & Fremont, D. H. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.07.003 · Cited by 52
Mattiuz, R., Wohn, C., Ghilas, S., Ambrosini, M., Alexandre, Y. O., Sanchez, C., Fries, A., Manh, T. V., MALISSEN, B., Dalod, M., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02805 · Cited by 61
“Constitutive (Batf3-KO mice) or conditional (ItgaxCre; Irf8fl/fl mice) genetic inactivation of transcription factors required for the differentiation of cDC1 allowed to study their specific functions in vivo (7, 8).”
BackgroundKuhn, N. F., Lopez, A. V., Li, X., Cai, W., Daniyan, A. F., & Brentjens, R. J. (2020) · Nature Communications · doi:10.1038/s41467-020-19833-3 · Cited by 56
Russler-Germain, E. V., Jung, J., Miller, A. T., Young, S., Yi, J., Wehmeier, A., Fox, L. E., Monte, K. J., Chai, J. N., Kulkarni, D. H., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.002 · Cited by 52
“In addition, Batf3 mutant mice deficient in cDC1s (Hildner et al., 2008) are more susceptible to Cp infection (Potiron et al.”
BackgroundImmune cellular components and signaling pathways in the tumor microenvironment
Yenyuwadee, S., Aliazis, K., Wang, Q., Christofides, A., Shah, R., Patsoukis, N., & Boussiotis, V. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.004 · Cited by 55
The persistent inflammation in COPD: is autoimmunity the core mechanism?
Dong, L., Liu, Z., Chen, K.-J., Li, Z., Zhou, J.-S., Shen, H., & Chen, Z. (2024) · European Respiratory Review · doi:10.1183/16000617.0137-2023 · Cited by 70
Chiriva‐Internati, M., Yu, Y., Mirandola, L., D’Cunha, N., Hardwicke, F. L., Cannon, M. J., Cobos, E., & Kast, W. M. (2011) · The Prostate · doi:10.1002/pros.21400 · Cited by 53
CpG Promotes Cross-Presentation of Dead Cell-Associated Antigens by Pre-CD8α+ Dendritic Cells
de Brito, C., Tomkowiak, M., Ghittoni, R., Caux, C., Leverrier, Y., & Marvel, J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001022 · Cited by 63
Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy
Kim, Y., Clements, D. R., Sterea, A. M., Jang, H. G., Gujar, S. A., & Lee, P. C. (2015) · Viruses · doi:10.3390/v7122953 · Cited by 63
“Both CD8+ and CD103+ cDC lineage development is governed by the same transcription factors: inhibitor of DNA binding 2 (Id2) [17], interferon regulatory factor 8 (IRF8) [18], basic leucine zipper transcriptional factor ATF-like 3 (BATF3) [19], and nuclear factor, interleukin 3 regulated (NFIL3) [20].”
BackgroundCross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy
Audsley, K. M., McDonnell, A. M., & Waithman, J. C. (2020) · Cells · doi:10.3390/cells9030565 · Cited by 58
Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
Schmiechen, Z. C., & Stromnes, I. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613815 · Cited by 68
“A specialized subset of conventional DCs (cDC1s) are efficient at cross-presenting tumor-associated antigen and appear essential for priming tumor-specific T cells (105).”
BackgroundPerry, J. S. A., & Hsieh, C. (2016) · Immunological Reviews · doi:10.1111/imr.12403 · Cited by 57
“Deletion of thymic CD8a DCs utilized germline knockouts of the basic leucine zipper transcription factor, ATF-like 3 (Batf3) (130).”
BackgroundSia, J., Hagekyriakou, J., Chindris, I., Albarakati, H., Leong, T., Schlenker, R., Keam, S. P., Williams, S., Neeson, P. J., Johnstone, R. W., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.05.014 · Cited by 56
Fate Mapping of Dendritic Cells
Poltorak, M. P., & Schraml, B. U. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00199 · Cited by 74
The Role of Insulin-Regulated Aminopeptidase in MHC Class I Antigen Presentation
Saveanu, L., & Endert, P. V. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00057 · Cited by 59
Development and homeostasis of dendritic cells
Liu, K., & Nussenzweig, M. C. (2010) · European Journal of Immunology · doi:10.1002/eji.201040501 · Cited by 62
Dendritic Cell Subsets in Asthma: Impaired Tolerance or Exaggerated Inflammation?
Vroman, H. H., Hendriks, R. W., & Kool, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00941 · Cited by 58
“Function of cDC1s in Asthma cDC1s are well appreciated for their superior cross-presentation of antigens to CD8+ T-cells, essential for induction of virusspecific CD8+ T-cells and antitumor immune responses (21, 24, 25).”
BackgroundCueto, F. J., del Fresno, C., & Sancho, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03146 · Cited by 56
Cupovic, J., Ring, S. S., Onder, L., Colston, J., Lütge, M., Cheng, H., Martin, A. D., Provine, N. M., Flatz, L., Oxenius, A., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00969-3 · Cited by 54
DCs at the center of help: Origins and evolution of the three-cell-type hypothesis
Wu, R., & MURPHY, K. M. M. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20211519 · Cited by 57
Bowman-Kirigin, J. A., Saunders, B. T., Desai, R., Wang, A. Z., Schaettler, M. O., Liu, C. J., Livingstone, A. J., Kobayashi, D. K., Durai, V., Kretzer, N. M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0098 · Cited by 62
Transcription factor networks in dendritic cell development
Satpathy, A. T., MURPHY, K. M. M., & Wumesh, K. C. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.08.009 · Cited by 61
“In contrast to the selective expression of IRFs within DC subsets, Batf3 is expressed in both CD8+ and CD4+ cDCs, but loss of Batf3 leads to an abrogation in the development of only one of these subsets, the CD8+ DC [96].”
BackgroundMHC Class I Cross-Presentation by Dendritic Cells Counteracts Viral Immune Evasion
Nopora, K., Bernhard, C., Ried, C., Castello, A. A., MURPHY, K. M. M., Marconi, P., Koszinowski, U. H., & Brocker, T. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00348 · Cited by 51
“…4 days and peptide concentration was 0.1 ng/ml. Frontiers in Immunology | Antigen Presenting Cell Biology November 2012 | Volume 3 | Article 348 | 2 defective development of CD8α+ and CD103+CD11b− DCs, the two major cross-presenting DC-subpopulations (Hildner et al., 2008; Edelson et al., 2010).”
BackgroundBoulet, S., Daudelin, J.-F., Odagiu, L., Pelletier, A.-N., Yun, T. J., Lesage, S., Cheong, C., & Labrecque, N. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821296116 · Cited by 51
“For example, the use of Batf3 mice has revealed the biological importance of IRF8 cDC1 cells in cross-priming and in the generation of resident memory T cells (4, 5).”
MethodPeptide Channeling: The Key to MHC Class I Immunosurveillance?
Yewdell, J. W., Dersh, D., & Fåhræus, R. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.09.004 · Cited by 57
Host Protective Immune Responses against Influenza A Virus Infection
Jung, H. E., & Lee, H. K. (2020) · Viruses · doi:10.3390/v12050504 · Cited by 72
Chen, L., Sun, R., Xu, J., Zhai, W., Zhang, D., Yang, M., Yue, C., Chen, Y., Li, S., Turnquist, H. R., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-1024 · Cited by 57
“To determine the role of CD103þ DC in mediating the antitumor function of IL33, we used Batf3 / mice, which had a selected deficiency in generating CD103þ DC (36, 37).”
MethodCancer Testis Antigen Vaccination Affords Long-Term Protection in a Murine Model of Ovarian Cancer
Chiriva‐Internati, M., Yu, Y., Mirandola, L., Jenkins, M., Chapman, C. J., Cannon, M. J., Cobos, E., & Kast, W. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010471 · Cited by 52
“Upon proper antigen presentation, activated DC play a key role in the induction of T cell responses[29,34,40,41,42].”
BackgroundPapaioannou, N. E., Salei, N., Rambichler, S., Rengarajan, K. R., Popović, J., Küntzel, V., Lehmann, C. H. K., Fiancette, R., Salvermoser, J., Gajdasik, D. W., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20659-2 · Cited by 57
The injury response to DNA damage in live tumor cells promotes antitumor immunity
Sriram, G., Milling, L. E., Chen, J.-K., Kong, Y. W., Joughin, B. A., Abraham, W. D., Swartwout, S., Handly, E. D., Irvine, D. J., & Yaffe, M. B. (2021) · Science Signaling · doi:10.1126/scisignal.abc4764 · Cited by 56
“Our results are in good agreement with recent studies wherein a subset of intratumoral DCs, characterized by their surface expression of CD103 in mice and blood dendritic cell antigen-3 (BDCA-3) in humans, was identified as having unique capabilities of crosspresenting tumor-associated antigens to CD8+ T cells and rec…”
BackgroundResultVersatile neutrophil functions in cancer
Siwicki, M. R., & Pittet, M. J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101538 · Cited by 56
Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities
Fu, C., Ma, T., Zhou, L., Mi, Q., & Jiang, A. (2022) · Immunological Investigations · doi:10.1080/08820139.2022.2109486 · Cited by 55
“…XCR1, and are developmentally dependent on transcription factors including the basic leucine zipper transcriptional factor ATF-like 3 (Batf3), interferon regulatory factor 8 (IRF8) and inhibitor of DNA binding 2 (Id2) (Guilliams et al. 2014; Gutierrez-Martinez et al. 2015; Hildner et al. 2008).”
BackgroundMAIT cells activate dendritic cells to promote TFH cell differentiation and induce humoral immunity
Pankhurst, T. E., Buick, K. H., Lange, J., Marshall, A. J., Button, K. R., Palmer, O. R., Farrand, K. J., Montgomerie, I., Bird, T. W., Mason, N. C., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112310 · Cited by 54
Dutertre, C., Jourdain, J.-P., Rancez, M., Amraoui, S., Fossum, E., Bogen, B., Sanchez, C., Couëdel-Courteille, A., Richard, Y., Dalod, M., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302448 · Cited by 55
“Particularly, in the three species, these cells expressed selectively high levels of the transcription factor Batf3, which specifically drives the development of XCR1 mouse (CD8a) and human (CD141) mDC at steady state (1, 62).”
BackgroundInnate immune sensing of cancer: clues from an identified role for type I IFNs
Gajewski, T. F., Fuertes, M. B., & Woo, S. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1305-6 · Cited by 54
“In vivo, they also have demonstrated a role for the CD8a DC lineage for spontaneous rejection of these tumors [28].”
BackgroundThe central role of antigen presentation in islets of Langerhans in autoimmune diabetes
Calderon, B., Carrero, J. A., & Unanue, E. R. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.10.011 · Cited by 50
The Mechanism of Splenic Invariant NKT Cell Activation Dictates Localization In Vivo
King, I. L., Amiel, E., Tighe, M., Mohrs, K., Veerapen, N., Besra, G. S., Mohrs, M., & Leadbetter, E. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300299 · Cited by 50
“diate iNKT cell activation in vivo during infection, we assessed iNKT cell activation following pneumococcal infection of batf3 mice, which have a specific deletion of splenic CD8 DCs (34).”
BackgroundSmyth, L. A., Hervouet, C., Hayday, T., Becker, P. D., Ellis, R., Lechler, R. I., Lombardi, G., & Klavinskis, L. S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200664 · Cited by 50
“Secondly, in Batf3 null mice that lack the dominant cross-presenting CD8a DEC205 DC subset (17), MHC class I:peptide transfer from”
BackgroundDesigning therapeutic cancer vaccines by mimicking viral infections
Sultan, H., Fesenkova, V. I., Addis, D., Fan, A. E., Kumai, T., Wu, J., Salazar, A. Μ., & Celis, E. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1834-5 · Cited by 53
“Because CD8a+ DCs are best suited for cross-priming CTLs [31], we will determine whether these APCs are responsible for TriVax and BiVax priming using CD8α+ DC-deficient mice [41].”
MethodSmyth, L. A., Lechler, R. I., & Lombardi, G. (2017) · American Journal of Transplantation · doi:10.1111/ajt.13996 · Cited by 50
“To test these hypotheses, MHC-class I transfer was evaluated in indirect (also referred to as crosspresentation or cross-priming) pathway deficient recipient mice (12), in the absence and presence of donor-derived DCs.”
BackgroundMinoda, Y., Virshup, I., Rojas, I. L., Haigh, O. L., Wong, Y., Miles, J. J., Wells, C. A., & Radford, K. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01419 · Cited by 50
“We identified a signature of 156 preferentially expressed genes that were shared by blood and hu mouse CD141+ DC regardless of their activation status, including many of the known hallmark genes such as CLEC9A, CADM1, ID2, and BATF3 (11, 38, 39).”
BackgroundMaschalidi, S., Nunes, P., Nascimento, C. R., Sallent, I., Lannoy, V., Garfa‐Traoré, M., Cagnard, N., Sepulveda, F. E., Vargas, P., Lennon‐Duménil, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01601-5 · Cited by 50
“TLR activation leads to (1) enhancement of antigen uptake by endocytosis and macropinocytosis, (2) MHCI recruitment to the phagosomes, (3) antigen translocation to the cytosol, and (4) reduction in the recruitment of active proteases to phagosomes5,6,11,12.”
BackgroundMethodFernandez‐Ruiz, D., Lau, L. S., Ghazanfari, N., Jones, C. M., Ng, W. Y., Davey, G. M., Berthold, D. L., Holz, L. E., Kato, Y., Enders, M. H., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700186 · Cited by 52
Tissue Site and the Cancer Immunity Cycle
Horton, B. L., Fessenden, T. B., & Spranger, S. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.006 · Cited by 60
Shaping of T Cell Functions by Trogocytosis
NAKAYAMA, M., Hori, A., Toyoura, S., & Yamaguchi, S.-I. (2021) · Cells · doi:10.3390/cells10051155 · Cited by 57
“Both studies demonstrated that DC2s have more potent cross-dressing activity than DC1s for antiviral immunity, although they did not use Batf3−/− mice [62,63].”
BackgroundInfluentialEarly events regulating immunity and pathogenesis during Listeria monocytogenes infection
Williams, M. A., Schmidt, R. L., & Lenz, L. L. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.04.007 · Cited by 47
Harnessing Human Cross-Presenting CLEC9A+XCR1+ Dendritic Cells for Immunotherapy
Tullett, K. M., Lahoud, M. H., & Radford, K. J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00239 · Cited by 55
“Expert Rev Vaccines (2013) 12(7):809–19.”
BackgroundInfluentialArtyomov, M. N., Munk, A., Gorvel, L., Korenfeld, D., Cella, M., Tung, T., & Klechevsky, E. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20131675 · Cited by 50
“Both mouse CD11b+ and CD4+ DCs are of similar origin and are BATF3 independent (Hildner et al., 2008).”
BackgroundUnanue, E. R., Ferris, S. T., & Carrero, J. A. (2016) · Immunological Reviews · doi:10.1111/imr.12430 · Cited by 56
“Batf3 / lacked the CD103/CD8a DC lineage of DCs in all lymphoid tissues, confirming the findings by the Murphy laboratory (90).”
ResultEmerging Role of the Unfolded Protein Response in Tumor Immunosurveillance
Vanacker, H., Vetters, J., Moudombi, L., Caux, C., Janssens, S., & Michallet, M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.05.005 · Cited by 53
Ghinnagow, R., Meester, J. D., Cruz, L. J., Aspord, C., Corgnac, S., Fernandez, É. M., Soulard, D., Fontaine, J., Chaperot, L., Charles, J., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1339855 · Cited by 51
Hu, Z., Li, Y., van Nieuwenhuijze, A. E. M., Selden, H. J., Jarrett, A. M., Sorace, A. G., Yankeelov, T. E., Liston, A., & Ehrlich, L. I. R. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.016 · Cited by 52
“To test our model that an increase in the frequency of Sirpα+DC results in an increased frequency of thymic Treg, we analyzed Batf3−/− thymi (Hildner et al., 2008), in which CD8+Sirpα− DC differentiation is impaired, resulting in an increased proportion of Sirpα+DC (Figure 7G).”
BackgroundRe-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
Ngiow, S. F., & Young, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01633 · Cited by 54
Pishesha, N., Harmand, T. J., Smeding, L. Y., Ma, W., Ludwig, L. S., Janssen, R., Islam, A., Xie, Y. J., Fang, T., McCaul, N., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00738-5 · Cited by 49
Davenport, B., Bullock, C. B., McCarthy, M. K., Hawman, D. W., MURPHY, K. M. M., Kedl, R. M., Diamond, M., & Morrison, T. E. (2020) · Journal of Virology · doi:10.1128/jvi.02036-19 · Cited by 54
Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity
Wang, Y., Song, M. L., Liu, M., Zhang, G., Zhang, X., Li, M. O., Ma, X., Zhang, J. J., & Huang, X. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108948 · Cited by 48
“In Batf3−/− mice, there are no cDC1 cells (Hildner et al., 2008).”
BackgroundBioinspired vaccines to enhance MHC class-I antigen cross-presentation
Baljon, J. J., & Wilson, J. T. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102215 · Cited by 57
The paradox of radiation and T cells in tumors
Gough, M. J., & Crittenden, M. R. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100808 · Cited by 55
Mabbott, N. A., & Gray, D. (2013) · Immunology · doi:10.1111/imm.12171 · Cited by 65
Transcriptional Regulation of Mononuclear Phagocyte Development
Tussiwand, R., & Gautier, E. L. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00533 · Cited by 48
“Identifying TFs or surface markers, which would compromise or trace the development of one lineage independently of the anatomical localization, as previously done in Batf3−/− mice for Irf8-dependent cDC1 would be of great advantage (69, 70).”
InfluentialIntegrin-targeted cancer immunotherapy elicits protective adaptive immune responses
Kwan, B. H., Zhu, E. F., Tzeng, A., Sugito, H. R., Eltahir, A., Ma, B., Delaney, M. K., Murphy, P. A., Kauke, M. J., Angelini, A., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160831 · Cited by 51
“Finally, to probe the function of DCs in this system, we used mice lacking the gene for the Batf3 transcription factor (Batf3 KO), which do not have the ability to mature CD8+ DCs and are thus deficient in cross-presentation (Hildner et al., 2008).”
MethodIdentification of Protective CD8 T Cell Responses in a Mouse Model of Zika Virus Infection
Hassert, M., Harris, M. G., Brien, J. D., & Pinto, A. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01678 · Cited by 51
de Silva, S., Fromm, G. J., Shuptrine, C. W., Johannes, K., Patel, A., Yoo, K. J., Huang, K., & Schreiber, T. H. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0493 · Cited by 51
“CD8aþDCs expressing the transcription factor BATF3 are essential for antitumor immunity (13) and have the unique ability to crosspresent exogenous tumor antigens, which gain entry to the cytosol of DCs following endocytosis, to CD8þ T cells.”
BackgroundLin, Y., Cheng, L., Liu, Y., Wang, Y., Wang, Q., Wang, H., Shi, G., Li, J., Wang, Q., Yang, Q., et al. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-0297-3 · Cited by 53
Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses
Pilones, K. A., Charpentier, M., García-Martínez, E., Daviaud, C., Kraynak, J., Aryankalayil, J. B., Formenti, S. C., & Demaria, S. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0338 · Cited by 50
Functions of Dendritic Cells and Its Association with Intestinal Diseases
Yang, Z., Wang, B., Wang, T., Wang, F., Guo, Y., Hua, R., Shang, H., Lü, X., & Xu, J. (2021) · Cells · doi:10.3390/cells10030583 · Cited by 51
“In the development of cDCs, basic leucine zipper ATF-like transcription factor 3 [20] and RELB proto-oncogene, which is also known as NF-κB subunit, are of great importance [21].”
BackgroundNovoszel, P., Drobits, B., Holcmann, M., Fernandes, C. D. S., Tschismarov, R., Derdak, S. V., Decker, T., Wagner, E. F., & Sibilia, M. C. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00765-4 · Cited by 50
“129 SvEv-Batf3 mice lack CD8α and CD103 cDC1s under homeostatic conditions [13, 42], whereas in a C57BL/6-background only a reduced splenic CD8α cDC1 population was observed [54, 55].”
BackgroundGeneration of cDC-like cells from human induced pluripotent stem cells via Notch signaling
Makino, K., Long, M. D., Kajihara, R., Matsueda, S., Oba, T., Kanehira, K., Liu, S., & Ito, F. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003827 · Cited by 55
Parmigiani, E., Ivánek, R., Rolando, C., Hafen, K., Turchinovich, G., Lehmann, F. M., Gerber, A., Brkić, Š., Frank, S., Meyer, S. C., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.06.006 · Cited by 48
Olivera, I., Bolaños, E., González-Gomariz, J., Hervás‐Stubbs, S., Mariño, K. V., Luri‐Rey, C., Etxeberría, I., Cirella, A., Egea, J., Glez‐Vaz, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100978 · Cited by 54
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments
Rayson, V., Harris, M. A., Savas, P. S., Hun, M. L., Virassamy, B., Salgado, R., & Loi, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.02.008 · Cited by 54
Metadata
- Authors
- Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., Schreiber, R. D., Murphy, T. L., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
- Corresponding author
- Murphy, Kenneth M.
- ORCID
- Venue
- Science
- Published
- 2008-11-14
- Volume
- 322
- Issue
- 5904
- Pages
- 1097-1100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2756611
- OpenAlex
- W2046505430
- Cited by
- 2,081
- References
- 29
- Citations by year
- 2026: 117 · 2025: 150 · 2024: 142 · 2023: 129 · 2022: 161 · 2021: 167 · 2020: 182 · 2019: 129 · 2018: 109 · 2017: 133 · 2016: 115 · 2015: 105 · 2014: 92 · 2013: 89 · 2012: 90
- FWCI
- 23.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- Batf3, CD8α+ dendritic cells, cross-presentation, West Nile virus, tumor rejection, dendritic cell development, transcription factors, antitumor immunity
- MeSH terms
- Animals, Antibodies, Viral, Cytotoxicity, Immunologic, Dendritic Cells, Female, Fibrosarcoma, Lymphocyte Activation, Male, Mice, Inbred C57BL, Repressor Proteins, Spleen, T-Lymphocytes, Cytotoxic, West Nile Fever, West Nile virus, CD4-Positive T-Lymphocytes, CD8 Antigens, Adoptive Transfer, Cross-Priming, Basic-Leucine Zipper Transcription Factors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.